Literature DB >> 25756439

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.

Joost Besseling1, John J P Kastelein1, Joep C Defesche2, Barbara A Hutten3, G Kees Hovingh1.   

Abstract

IMPORTANCE: Familial hypercholesterolemia is characterized by impaired uptake of cholesterol in peripheral tissues, including the liver and the pancreas. In contrast, statins increase the cellular cholesterol uptake and are associated with increased risk for type 2 diabetes mellitus. We hypothesize that transmembrane cholesterol transport is linked to the development of type 2 diabetes.
OBJECTIVE: To assess the association between type 2 diabetes prevalence and familial hypercholesterolemia. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study in all individuals (n = 63,320) who underwent DNA testing for familial hypercholesterolemia in the national Dutch screening program between 1994 and 2014. EXPOSURES: Deleteriousness and nondeleteriousness of familial hypercholesterolemia mutations were based on literature or laboratory function testing. Low-density lipoprotein (LDL) receptor mutations were considered more severe than apolipoprotein B gene (APOB) mutations, and receptor-negative LDL receptor mutations were considered more severe than receptor-deficient mutations. MAIN OUTCOMES AND MEASURES: Prevalence of type 2 diabetes.
RESULTS: The prevalence of type 2 diabetes was 1.75% in familial hypercholesterolemia patients (n = 440/25,137) vs 2.93% in unaffected relatives (n = 1119/38,183) (P < .001; odds ratio [OR], 0.62 [95% CI, 0.55-0.69]). The adjusted prevalence of type 2 diabetes in familial hypercholesterolemia, determined using multivariable regression models, was 1.44% (difference, 1.49% [95% CI, 1.24%-1.71%]) (OR, 0.49 [95% CI, 0.41-0.58]; P < .001). The adjusted prevalence of type 2 diabetes by APOB vs LDL receptor gene was 1.91% vs 1.33% (OR, 0.65 [95% CI, 0.48-0.87] vs OR, 0.45 [95% CI, 0.38-0.54]), and the prevalence for receptor-deficient vs receptor-negative mutation carriers was 1.44% vs 1.12% (OR, 0.49 [95% CI, 0.40-0.60] vs OR, 0.38 [95% CI, 0.29-0.49]), respectively (P for trend <.001 in both comparisons). CONCLUSIONS AND RELEVANCE: In a cross-sectional analysis in the Netherlands, the prevalence of type 2 diabetes among patients with familial hypercholesterolemia was significantly lower than among unaffected relatives, with variability by mutation type. If this finding is confirmed in longitudinal analysis, it would raise the possibility of a causal relationship between LDL receptor-mediated transmembrane cholesterol transport and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25756439     DOI: 10.1001/jama.2015.1206

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  97 in total

Review 1.  The evolution of domain arrangements in proteins and interaction networks.

Authors:  E Bornberg-Bauer; F Beaussart; S K Kummerfeld; S A Teichmann; J Weiner
Journal:  Cell Mol Life Sci       Date:  2005-02       Impact factor: 9.261

Review 2.  Association between apolipoprotein B EcoRI polymorphisms and coronary heart disease : A meta-analysis.

Authors:  Yeda Chen; Jingtang Zeng; Yiqing Tan; Min Feng; Jiheng Qin; Meihua Lin; Xiang Zhao; Xiaolei Zhao; Yan Liang; Naizun Zhang; Shaoqi Rao
Journal:  Wien Klin Wochenschr       Date:  2016-09-08       Impact factor: 1.704

Review 3.  Diabetes Secondary to Treatment with Statins.

Authors:  Markku Laakso; Johanna Kuusisto
Journal:  Curr Diab Rep       Date:  2017-02       Impact factor: 4.810

Review 4.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

5.  Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish.

Authors:  Huichun Xu; Kathleen A Ryan; Thomas J Jaworek; Lorraine Southam; Jeffrey G Reid; John D Overton; Aris Baras; Marja K Puurunen; Eleftheria Zeggini; Simeon I Taylor; Alan R Shuldiner; Braxton D Mitchell
Journal:  Diabetes       Date:  2017-04-20       Impact factor: 9.461

Review 6.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

Review 7.  Statins: pros and cons.

Authors:  Iago Pinal-Fernandez; Maria Casal-Dominguez; Andrew L Mammen
Journal:  Med Clin (Barc)       Date:  2017-12-29       Impact factor: 1.725

8.  Pancreatic PCSK9 and its involvement in diabetes.

Authors:  Maaike Kockx; Leonard Kritharides
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

9.  Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.

Authors:  Emil M deGoma; Zahid S Ahmad; Emily C O'Brien; Iris Kindt; Peter Shrader; Connie B Newman; Yashashwi Pokharel; Seth J Baum; Linda C Hemphill; Lisa C Hudgins; Catherine D Ahmed; Samuel S Gidding; Danielle Duffy; William Neal; Katherine Wilemon; Matthew T Roe; Daniel J Rader; Christie M Ballantyne; MacRae F Linton; P Barton Duell; Michael D Shapiro; Patrick M Moriarty; Joshua W Knowles
Journal:  Circ Cardiovasc Genet       Date:  2016-03-24

Review 10.  Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council.

Authors:  Robert A Hegele; Samuel S Gidding; Henry N Ginsberg; Ruth McPherson; Frederick J Raal; Daniel J Rader; Jennifer G Robinson; Francine K Welty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-09-16       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.